scispace - formally typeset
N

Nicola Ferri

Researcher at University of Padua

Publications -  212
Citations -  5928

Nicola Ferri is an academic researcher from University of Padua. The author has contributed to research in topics: PCSK9 & Medicine. The author has an hindex of 35, co-authored 175 publications receiving 4692 citations. Previous affiliations of Nicola Ferri include University of Milan & University of Washington.

Papers
More filters
Journal ArticleDOI

Non-lipid-related effects of statins

TL;DR: The present review discusses the current knowledge on the non-lipid-related effects of statins, with a special emphasis on their potential benefits in different diseases, such as atherosclerosis and cancer.
Journal ArticleDOI

Direct vascular effects of HMG-CoA reductase inhibitors

TL;DR: Results suggest that HMG-CoA reductase inhibitors exert a direct antiatherosclerotic effect in the arterial wall, beyond their effects on plasma lipids, that could translate into a more significant prevention of cardiovascular disease.
Journal ArticleDOI

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.

TL;DR: Data indicate that PCSK9 secreted by human SMCs is functionally active and capable of reducing LDLR expression in macrophages, suggesting a possible direct role for this protein in foam cell formation and atherogenesis.
Journal ArticleDOI

Thematic Review Series: The Immune System and Atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease

TL;DR: This review summarizes in vivo studies that have characterized endothelial- and smooth muscle-specific effects of altering cytokine signaling in vascular disease and underscores the need to delineate the critical genes and specific cellular functions regulated by individual cytokine signaled pathways.
Journal ArticleDOI

Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity

TL;DR: In this paper, the authors summarized the clinical manifestations of drug-induced cardiotoxicity by various cancer chemotherapies and novel drugs for the treatment of other diseases and presented guidelines for the management of patients exposed to drugs with cardiotoxic potential.